Jordan’s MS Pharma is expanding its geographic footprint with the acquisition of European pharma firm, Genepharm.
Based in Greece, Genepharm develops, manufactures and out-licenses high-value generic pharmaceutical products.
The company retains a strong portfolio of products and an extensive network of over 223 customers across 70 countries worldwide.
Genepharm combines strong R&D capabilities with manufacturing capacity in conventional solids, sterile liquid (oncology) and oncology oral solids.
MS Pharma said the acquisition allow it to reach more patients and customers in Europe and the rest of the world.
It will complement MS Pharma’s existing chronic disease portfolio with the addition of several important products in cardiovascular, CNS and oncology.
The acquisition will allow Genepharm to access MS Pharma’s manufacturing facilities and products portfolio and be part of a group employing over 2000 employees.
Genepharm’s portfolio will be strengthened with sterile injectable products and biotechnology candidates and plans are in place to significantly increase the development resources in Athens.
Genepharm’s senior management will remain with the business and help guide the company through the next phase of its growth. The transaction is expected to close by the end of April.